Becotatug Vedotin
Phase 3Antibody–drug conjugate
Becotatug Vedotin is one of 264 small molecule programs targeting Efficacy and Safety. It is currently in Phase 3.
13
Indications
16
Total Trials
16
Active Trials
263
Competitors
Pipeline
Status by Indication[3][1]
Indication
Showing 10 of 13 indications
Competition
Competitive Landscape
268 competitors in Colorectal Cancer
#DrugCompanyPhaseTrials
1Bayer Aspirin
BayerPhase 3
Mitosol
UUroGen Pharma Ltd.
Phase 3
Trifluridine/tipiracil
AbbViePhase 3
Telisotuzumab Adizutecan
AbbViePhase 3
XL092
RochePhase 3
5-Fu
TToray Industries, Inc
Phase 3
PD-1 Monoclonal Antibody
SSichuan Baili Pharmaceutical Co., Ltd.
Phase 3
Becotatug Vedotin
FFudan University
Phase 3
IBI363
Innovent Biologics (Suzhou) Co. Ltd.Phase 3
Calcium Levofolinate
FFujian Cancer Hospital
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Penile Cancer2 trials
Head and Neck Squamous Cell Carcinoma2 trials
Nasopharyngeal Carcinoma1 trial
Efficacy and Safety1 trial
9 more indications
Becotatug Vedotin1 trial
Becotatug Vedotin Plus Sintilimab in Locoregionally Advanced NPC
Recruiting·FFirst Affiliated Hospital of Guangxi Medical University·Phase 3·NCT07459296·266 enrolled
Colorectal Cancer1 trial
Metastatic Pancreatic Adenocarcinoma1 trial
Oral Squamous Cell Carcinoma1 trial
Adenoid Cystic Carcinoma1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Becotatug Vedotin. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Antibody–drug conjugate[2]
- Highest Phase
- Phase 3[1]
- Company
- FFudan University